Mural Oncology (MURA) Stock Price, News & Analysis

Company Overview

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

Key Stats

• Today's Range: $3.10 to $3.30
• 50-Day Range: $3.14 to $4.18
• 52-Week Range: $2.87 to $6.25
• Volume: 205,243 shs
• Average Volume: 185,512 shs
• Market Capitalization: $54.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.00
• Consensus Rating: Buy

Mural Oncology Stock Analysis - MarketRank™

Mural Oncology scored higher than 59% of companies evaluated by MarketBeat, and ranked 390th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Mural Oncology has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Mural Oncology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mural Oncology are expected to grow in the coming year, from ($7.54) to ($4.72) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Mural Oncology is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Mural Oncology is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Mural Oncology has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.07% of the float of Mural Oncology has been sold short.

Short Interest Ratio / Days to Cover

Mural Oncology has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mural Oncology has recently increased by 28.94%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mural Oncology does not currently pay a dividend.

Dividend Growth

Mural Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.07% of the float of Mural Oncology has been sold short.

Short Interest Ratio / Days to Cover

Mural Oncology has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Mural Oncology has recently increased by 28.94%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for MURA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

5 people have added Mural Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Mural Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $25,306.00 in company stock.

Percentage Held by Insiders

Only 0.06% of the stock of Mural Oncology is held by insiders.

Percentage Held by Institutions

80.21% of the stock of Mural Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MURA Stock Analysis - Frequently Asked Questions

How have MURA shares performed this year?

Mural Oncology's stock was trading at $5.92 at the beginning of 2024. Since then, MURA stock has decreased by 46.3% and is now trading at $3.18.
View the best growth stocks for 2024 here.

Who are Mural Oncology's major shareholders?

Top institutional investors of Mural Oncology include RBF Capital LLC (2.11%), Verition Fund Management LLC (2.00%), Centiva Capital LP (1.20%) and Geode Capital Management LLC (1.12%). Insiders that own company stock include Caroline Loew and Adam D Cutler.
View institutional ownership trends.

How do I buy shares of Mural Oncology?

Shares of MURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Mural Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mural Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), General Electric (GE) and Adobe (ADBE).

Company Calendar

• Today: 12/22/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MURA
• Previous Symbol: NASDAQ:MURA
• CUSIP: N/A
• CIK: 1971543
• Web: www.muraloncology.com
• Phone: 353-1-905-8020
• Fax: N/A
• Employees: 119
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $16.00
• High Stock Price Target: $18.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +403.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($9.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-207,450,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -70.10%
• Return on Assets: -61.30%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.38
• Quick Ratio: 7.38

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.81 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 17,020,000
• Free Float: 17,010,000
• Market Cap: $54.12 million
• Optionable: Optionable
• Beta: N/A